...
首页> 外文期刊>癌と化学療法 >Non-randomized clinical study comparing chemotherapy plus radiotherapy with radiotherapy alone in neoadjuvant therapy for oral cancer
【24h】

Non-randomized clinical study comparing chemotherapy plus radiotherapy with radiotherapy alone in neoadjuvant therapy for oral cancer

机译:非随机临床研究比较化学疗法加放疗与单纯放疗在口腔癌新辅助治疗中的比较

获取原文
获取原文并翻译 | 示例

摘要

Neoadjuvant therapy plays an important role for organ preservation and survival rate in the treatment of oral cancer. We clinically compared the effect of neoadjuvant radiotherapy and chemoradiotherapy in patients with oral cancer. We retrospectively examined 47 patients diagnosed with oral squamous cell carcinoma who underwent neoadjuvant therapy followed by curative surgery in the oral and maxillofacial surgery department of Ehime University Hospital. We divided them into two groups: radiotherapy alone (24 cases) and chemoradiotherapy (23 cases). The patients in the radiotherapy group underwent irradiation of 32.6 +/- 5.0 Gy (mean +/- SD). The patients in the chemoradiotherapy group received a low-dose fraction of cisplatin (8 mg/mm2/day, 5 days a week; total dose: 139.4 +/- 67.1 mg) and 5-fluorouracil (300 mg/mm2/day, 5 days a week; total dose: 5,900 +/- 1,839.8 mg) combined with simultaneous irradiation of 31.0 +/- 3.2 Gy. None of the 24 patients had a complete response to radiotherapy alone and 12(50%) had a partial response. Six (26%) of the 23 patients had a complete response to chemoradiotherapy and 12 (52%) had a partial response. The primary control rate (82.6%) to chemoradiotherapy was higher than that (67.5%) to radiotherapy alone although no significant difference was found. The 5-year survival rate was 64.3% in the radiotherapy group and 62.8% in the chemoradiotherapy group. The findings of the present study suggest that while the combination of radiation and cisplatin/5-fluorouracil in neoadjuvant therapy for oral cancer may not bring a significant benefit to improve survival rate, the primary local control rate is improved in comparison with radiotherapy alone.
机译:新辅助疗法在口腔癌的治疗中对于器官保存和存活率起重要作用。我们在临床上比较了新辅助放疗和放化疗在口腔癌患者中的作用。我们回顾了爱媛大学医院口腔颌面外科的47例经诊断为口腔鳞状细胞癌的患者,他们接受了新辅助治疗,然后进行了根治性手术。我们将其分为两组:单独放疗(24例)和放化疗(23例)。放射治疗组的患者接受了32.6 +/- 5.0 Gy的放射线(平均+/- SD)。放化疗组的患者接受低剂量顺铂(8 mg / mm2 /天,每周5天;总剂量:139.4 +/- 67.1 mg)和5-氟尿嘧啶(300 mg / mm2 /天,5一周;总剂量:5,900 +/- 1,839.8 mg),同时照射31.0 +/- 3.2 Gy。 24例患者中没有一个对放疗有完全缓解,12例(50%)有部分缓解。 23例患者中有6例(26%)对放化疗完全缓解,12例(52%)部分缓解。放化疗的主要控制率(82.6%)高于单纯放疗的主要控制率(67.5%),但无显着差异。放疗组的5年生存率为64.3%,放化疗组的为62.8%。本研究的发现表明,尽管放射线疗法和顺铂/ 5-氟尿嘧啶的组合在口腔癌新辅助治疗中可能不会带来显着的改善生存率的益处,但与单纯放疗相比,主要的局部控制率有所提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号